Navigation Links
VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
Date:1/7/2008

-- our ability to successfully complete our clinical trials of VIA-2291

on expected timetables and the outcomes of such clinical trials;

-- the results of our clinical trials, including without limitation, with

respect to the safety and efficacy of VIA-2291;

-- the outcome of any legal proceedings;

-- our ability to obtain necessary FDA approvals;

-- our ability to successfully commercialize VIA-2291;

-- our ability to obtain and protect our intellectual property related to

our product candidates;

-- our potential for future growth and the development of our product

pipeline;

-- our ability to form and maintain collaborative relationships to

develop and commercialize our product candidates;

-- general economic and business conditions; and

-- the other risks described under the heading "Risk Factors" in our

Quarterly Reports on Form 10-Q for the quarters ended June 30, 2007

and September 30, 2007 on file with the SEC.

All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above. Forward-looking statements speak only as of the date they are made, and VIA undertakes no obligation to update publicly any of these statements in light of new information or future events.


'/>"/>
SOURCE VIA Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 11, 2014  Major advances in radiation therapy ... being highlighted in a three-day Oncology Summit taking ... July, 2014.  Renowned national and international cancer experts from ... and exchange knowledge on modern technologies making treatment ... The Summit will address a ...
(Date:7/10/2014)... NEWPORT NEWS, Virginia , 11. ... führender Hersteller von Kameras für die ... Brust (MBI/BSGI), hat heute die CE-Zulassung ... Mit dem CE-Zeichen kann Dilon das ... seinen Vertriebsbereich auf den Großteil der ...
(Date:7/10/2014)... U.S. Department of Health and Human Services (HHS) has ... Medical Center Seidman Cancer Center totaling $4.7 million to ... for patients with complex cancer. Titled ... model developed at UH to enhance care for adult ... need for high health care utilization.  ...
Breaking Medicine Technology:Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... 2011 Vanda Pharmaceuticals Inc. (Nasdaq: VNDA ... granted orphan drug designation for tasimelteon, an oral dual ... Non-24-Hour Sleep/Wake Disorder (N24HSWD) in blind individuals with no ... designation that the Committee for Orphan Medicinal Products (COMP) ...
... China, March 8, 2011 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ... a leading pharmaceutical company specializing in the development, manufacturing, ... today reported unaudited financial results for the fourth quarter ... Highlights Total revenue was ...
Cached Medicine Technology:Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon 2Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon 3Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon 4Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 2Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 3Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 4Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 5Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 6Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 7Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 8Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 9Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 10Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 11Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 12
(Date:7/11/2014)... This morning(July 9th, 2014 at 8 am), ... discuss the illegal immigration crisis at our southern border and ... , Dr. Flinn told Good Morning Memphis host Ernie Freeman, ... The problem is that they do not have enough agents ... day are coming into the border; the border isn’t protected.” ...
(Date:7/11/2014)... 11, 2014 People with physical disabilities ... some of the increasing numbers of people partnered with ... independent and productive lives. , But are these ... an assistance dog an impediment to employment? , ... August 3 - 9, 2014, West Virginia University associate ...
(Date:7/11/2014)... July 11, 2014 The Williams Rejuva ... part of each patient’s unique treatment regime. Using ... skin’s health and trouble areas can be quickly created. ... to be established. , Vectra 3D is a cutting-edge ... Vectra 3D uses a quick ‘snapshot’ of the skin ...
(Date:7/11/2014)... Texas (PRWEB) July 11, 2014 Yisrayl Hawkins, ... Texas, writes a letter pleading to let the children from ... to be allowed to come. Yisrayl says President Barack Obama ... need from the United States, and he wants to help ... children coming from Guatemala, Honduras and El Salvador being treated ...
(Date:7/11/2014)... Even the hot Texas sun won’t keep kids from having ... The school had previously invested in a playground structure to ... recently asked for an innovative solution to help protect children ... chose a Rectangular Shade from APCPLAY as the perfect solution ... The shade measures 24’W x 34’H x 11’H to ...
Breaking Medicine News(10 mins):Health News:Senate Candidate, George Flinn on Fox13 NEWS About the Border Crisis 2Health News:Will Your Next Employee or Co-Worker Be a Dog? 2Health News:Will Your Next Employee or Co-Worker Be a Dog? 3Health News:Will Your Next Employee or Co-Worker Be a Dog? 4Health News:Williams Rejuva Center Includes Innovative Computer Imaging 2Health News:Yisrayl Hawkins Backs Barack Obama’s Pleas to Let the Children Come to the U.S. in New Letter 2Health News:Yisrayl Hawkins Backs Barack Obama’s Pleas to Let the Children Come to the U.S. in New Letter 3Health News:Cool Fun Under the Texas Sun: Godley Elementary School Purchases Shade Structure from APCPLAY© 2
... working to ... Oct. 15 More than half of the children in,Indianapolis ... University School of Dentistry mobile project had moderate or,severe dental ... by the,university and funded in part by a grant from ...
... mathematician who has applied mathematical modeling techniques to elucidate the ... methods to ascertain the players most deserving of major league ... awards. Bukiet, a popular NJIT math professor, dives annually ... game, but also for his love of teaching and math. ...
... DUBLIN, Ohio, Oct. 15 Foresight Corporation ... Debra Strickland has joined the,company,s Development division ... http://www.newscom.com/cgi-bin/prnh/20081015/CLW134 ), In this role, ... customers to,propose and design new technical solutions, ...
... 15 deCODE genetics,(Nasdaq: DCGN ) today ... review of,its long-term business strategy. Over the past ... chemistry, structural biology and,human genetics to develop product ... diagnostics. The goal of this strategic,review is to ...
... Thanks Donor Family for New Hand, LOUISVILLE, Ky., ... transplant recipient headed home,yesterday (Oct. 14) to Upland, California, ... new right hand during a 14-hour surgical,procedure performed by ... on July 12, 2008 at Jewish Hospital., "I ...
... Cenegenics Education and Research Foundation partnered with two recognized ... of Medicine to examine testosterone and/or human growth hormone ... body composition and quality of life. Favorable findings from ... Journal of Multidisciplinary Healthcare, part of Dove Open Access. ...
Cached Medicine News:Health News:SEAL Indiana Reports More Than Half of Indianapolis Area School Kids Treated by Program Have Moderate or Severe Dental Decay 2Health News:Using math model, NJIT professor names MVP and Cy Young award contenders 2Health News:Using math model, NJIT professor names MVP and Cy Young award contenders 3Health News:Debra Strickland joins Foresight Corporation in time for HIPAA 5010 Mandate 2Health News:deCODE Conducting Strategic Review to Sharpen the Focus of its Long-term Business 2Health News:deCODE Conducting Strategic Review to Sharpen the Focus of its Long-term Business 3Health News:deCODE Conducting Strategic Review to Sharpen the Focus of its Long-term Business 4Health News:Fourth Hand Transplant Recipient Heads Home to California 2Health News:Hormone Normalization Shows Encouraging Effects In Documented Clinically Deficient Men/Women 2Health News:Hormone Normalization Shows Encouraging Effects In Documented Clinically Deficient Men/Women 3
... when it comes to superior immobilization and cervical ... job., ,You already know that the most ... of the c-spine. But what you may not ... Medical's NECLOC ®: provides superior immobilization over the ...
Distinct male and female designs for proper anatomical fit. Hip and pelvic components sized independently. Rigid posterior tongue minimizes pelvic rotation. Available in black or white plastic. Aggre...
... The B3 Triplanar hip joint ... Flexion - extension, abduction - ... on our Boston Post-Op Hip ... our custom Hip Spicas in ...
... Impact is the most significant advance in walker design ... unique design where the weight bearing surfaces of the ... impact is absorbed at the heel strike. The footbed ... the foot for added comfort and stability. , ...
Medicine Products: